Nanomedicine associated with photodynamic therapy for glioblastoma treatment.

about

Gold nanourchins and celastrol reorganize the nucleo- and cytoskeleton of glioblastoma cells.Preclinical outcomes of Intratumoral Modulation Therapy for glioblastoma.

P2860

Q47225712-D58010F7-C654-4463-9247-08B78331738F Q55003877-6EE06370-A18C-4B7A-8CF3-3A03E9D9E193

P2860

Nanomedicine associated with photodynamic therapy for glioblastoma treatment.

Item

http://www.wikidata.org/entity/Q47097576

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Nanomedicine associated with photodynamic therapy for glioblastoma treatment.

@en

Nanomedicine associated with photodynamic therapy for glioblastoma treatment.

@nl

type

Item

label

Nanomedicine associated with photodynamic therapy for glioblastoma treatment.

@en

Nanomedicine associated with photodynamic therapy for glioblastoma treatment.

@nl

prefLabel

Nanomedicine associated with photodynamic therapy for glioblastoma treatment.

@en

Nanomedicine associated with photodynamic therapy for glioblastoma treatment.

@nl

P1476

Nanomedicine associated with photodynamic therapy for glioblastoma treatment.

@en

P2093

Antonio C Tedesco

http://www.w3.org/2001/XMLSchema#string

Fernando L Primo

http://www.w3.org/2001/XMLSchema#string

Leonardo B de Paula

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

The 2007 WHO classification of tumours of the central nervous system

P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A review

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Untangling the ErbB signalling network

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Identification of human brain tumour initiating cells

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

P2888

s12551-017-0293-3

P304

761-773

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12551-017-0293-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28823025

http://www.w3.org/2001/XMLSchema#string

P932

5662035

http://www.w3.org/2001/XMLSchema#string

Nanomedicine associated with photodynamic therapy for glioblastoma treatment.

about

P2860

P2860

Nanomedicine associated with photodynamic therapy for glioblastoma treatment.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P932